NASH

July 14, 2016July 14, 2016

NASH May Be Prevented in Hepatitis Patients by Blocking Inflammatory Cytokine

The proinflammatory cytokine IL-17 drives the development of non-alcoholic steatohepatitis, or NASH — a disease that often leads to liver cancer, researchers at the National Cancer Research Centre (CNIO), in Spain, ... Read more

June 16, 2015June 16, 2015

Tobira Finishes Patient Enrollment for NASH Study

News

Tobira Therapeutics, Inc. has finished recruiting patients for its phase 2b CENTAUR study, which was designed to evaluate a therapy called cenicriviroc (CVC) in patients who suffer from non-alcoholic steatohepatitis (NASH) ... Read more

February 12, 2015February 17, 2015

Breakthrough Therapy Status Granted to Intercept’s Nonalcoholic Steatohepatitis Drug

NASH, News

The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to pipeline product obeticholic acid (OCA), developed by Intercept Pharmaceuticals, Inc. for the treatment of nonalcoholic steatohepatitis (NASH) with liver fibrosis. ... Read more

January 22, 2015January 22, 2015

Gilead Sciences Acquires Phenex Pharma’s Platform for Non-Alcoholic Steatohepatitis

News

Gilead Sciences, Inc. and Phenex Pharmaceuticals AG, announced the establishment of a contract in which Gilead is set to acquire the Farnesoid X Receptor (FXR) program of Phenex for the application of small molecule FXR agonists to treat liver ... Read more